Veradermics Q3 net loss widens as G&A expenses surge
MANE•Veradermics’ third-quarter net loss widened slightly to $21 million as general and administrative expenses rose $10.5 million year over year. The company ended the quarter with $798 million in cash, which it expects to fund operations into 2030.
1. Quarterly results
Veradermics reported a third-quarter net loss of $21 million and operating expenses of $28.78 million. Research and development expenses fell $2 million year over year, mainly because of lower clinical and development costs for VDPHL01, while G&A expenses rose $10.5 million on higher payroll, stock-based compensation, commercial readiness costs and professional fees.
2. Cash and outlook
The company ended the quarter with $798 million in cash and said it expects the balance to fund operations into 2030. It expects topline data from Phase 2/3 Study 306 in the first half of 2027.
